Table 1.
Study sample characteristics for kidney and cardiovascular phenotypes.
| Consortium | Sample sizea | No. of studiesb | Female sex | Age (y) | DM | HTN | Key phenotype | Values corresponding to key phenotype |
|---|---|---|---|---|---|---|---|---|
| CKDGen – eGFR23 | 67,093d | 20 | 72% (48,637) | 59.0 (11.8) | 8% (5,343) | 37% (24,798) | eGFRcr | 86.89 ± 21.62 ml/min/1.73 m2 |
| CKDGen – UACR24 | 31,580 | 12 | 53% (16,723) | 56.4 | 9% (2,818) | 38% (12,001) | UACR | 6.03 [3.52-11.75] mg/gc |
| ICBP17 | 69,395 | 29 | 55% (37,956) | 51.0 (9.9) | NA | 33% (22,573) | SBP/DBP | 129.91 ± 18.38 / 78.54 ± 10.63 mm Hg |
| CARDIoGRAM18 | 86,995 | 14 | 51% (44,505) | 56.0 (9.4) | NA | NA | MI | 52,120 (60) |
| CHARGE IMT19 | 31,181 | 9 | 55% (17,294) | 59.1 (10.3) | 9% (2,661) | 45% (13,996) | cIMT | 0.84 ± 1.6 mm |
| AortaGen20 | 20,634 | 9 | 55% (11,252) | 59.2 (11.3) | NA | NA | Inverse PWV | 125.11 ± 33 ms/m |
| CHARGE Eye21 | 15,358 | 4 | 57% (8,682) | 70.7 (5.8) | NA | NA | RVC | 141.55 ± 14.45 μm |
| NeuroCHARGE22 | 12,385 | 9 | 58% (7,168) | 69.8 (6.3) | 10% (1,250) | 55% (6,833) | WML burden | 4.43 ± 5.35 mL |
Note: Except where otherwise indicated, values for categorical variables are given as number (percentage); values for continuous variables, as mean +/- standard deviation.
DM, diabetes; HTN, hypertension; eGFR, estimated glomerular filtration rate; eGFRcr, creatinine-based eGFR; eGFRcys, cystatin C-based eGFR; UACR, urinary albumin-creatine ratio; CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; MI, myocardial infarction; IMT, intima-media thickness; cIMT, carotid intima-media thickness; PWV, pulse-wave velocity; RVC, retinal venular caliber; WML, white matter lesion ICBP (International Consortium for Blood Pressure); CARDIoGRAM (Coronary Artery Disease Genome-wide Replication and Meta-Analysis); CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology; NA, not available
Refers to the recruited sample for the respective phenotype, which may differ from the successfully genotyped and analyzed sample.
Details on the individual cohorts included are available in the supplemental materials of the original papers.
Median [interquartile range].
Sample size for cystatin C-based eGFR (eGFRcys) was 20,966.